Head and Neck Cancers

9 protocols meet the specified criteria.
  • 20324

    ON-TRK: PrOspective Non-Interventional Study in Patients with Locally Advanced or Metastatic TRK Fusion Cancer Treated with Larotrectinib
  • DB-020-002

    Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Doses of DB-020 in Patients Receiving Cisplatin
  • EAY131

    Molecular Analysis for Therapy Choice (MATCH)
  • GTI-4419-301

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Superoxide Dismutase Mimetic GC4419 to Reduce Severe Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer
  • INCB54828-207

    A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
  • NETSPOT

    A Comparison of NETSPOT Imaging Versus 18F-FDG-PET/CT in Head and Neck Cancer Patients
  • NRG-HN004

    Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Stage III-IVB Head and Neck Cancer With a Contraindication to Cisplatin
  • RTOG1216

    Randomized Phase II/III Trial of Surgery and Postoperavtive Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
  • SIMPRO

    SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice.